Upregulating KTN1 promotes Hepatocellular Carcinoma progression

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Hepatocellular carcinoma (HCC) is a prevalent global malignancy.
• Kinectin 1 (KTN1) is a frequently identified antigen in HCC tissues, but its specific roles are unclear.

Purpose of the Study:

• To investigate the expression status and clinical significance of KTN1 in HCC.
• To explore the biological functions and underlying mechanisms of KTN1 in HCC progression.

Main Methods:

• RT-qPCR and analysis of external gene datasets (microarrays, RNA-seq) to determine KTN1 expression.
• Kaplan-Meier curves and forest plots to assess prognostic value.
• CRISPR/Cas9 gene editing to knock out KTN1 in HCC cells, followed by functional assays (viability, migration, invasion, cell cycle, apoptosis) and RNA sequencing.

Main Results:

• KTN1 expression is significantly elevated in HCC tissues and correlates with poorer patient prognosis, identifying it as a potential independent risk factor.
• KTN1 knockout inhibited HCC cell viability, migration, and invasion, induced G0-G1 cell cycle arrest, and increased apoptosis.
• RNA sequencing revealed significant alterations in pathways like innate immune response and chemical carcinogenesis post-KTN1 knockout.

Conclusions:

• Elevated KTN1 expression serves as a prognostic biomarker for HCC.
• KTN1 promotes HCC development and progression by enhancing cell survival, migration, invasion, cell cycle progression, and inhibiting apoptosis.
• KTN1 represents a potential therapeutic target for HCC.